
Elite Pharmaceuticals
(OTC) ELTP
Elite Pharmaceuticals Financials at a Glance
Market Cap
$365.29M
Revenue (TTM)
$140.12M
Net Income (TTM)
$43.41M
EPS (TTM)
$0.02
P/E Ratio
15.56
Dividend
$0.00
Beta (Volatility)
0.45 (Low)
Dividend
$0.00
Beta (Volatility)
0.45 (Low)
Price
$0.34
Volume
1,317,874
Open
$0.35
Price
$0.34
Volume
1,317,874
Open
$0.35
Previous Close
$0.34
Daily Range
$0.33 - $0.36
52-Week Range
$0.33 - $0.82
Estimated Earnings Date
Feb 17, 2026
Dividend
$0.00
Beta (Volatility)
0.45 (Low)
Price
$0.34
Volume
1,317,874
Open
$0.35
Previous Close
$0.34
Daily Range
$0.33 - $0.36
52-Week Range
$0.33 - $0.82
Estimated Earnings Date
Feb 17, 2026
ELTP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Elite Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
68
CEO
Nasrat A. Hakim
Website
www.elitepharma.comHeadquarters
Northvale, NJ 07647, US
ELTP Financials
Key Financial Metrics (TTM)
Gross Margin
51%
Operating Margin
36%
Net Income Margin
31%
Return on Equity
74%
Return on Capital
44%
Return on Assets
34%
Earnings Yield
6.43%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$365.29M
Shares Outstanding
1.08B
Volume
1.32M
Avg. Volume
550.43K
Financials (TTM)
Gross Profit
$40.09M
Operating Income
$19.60M
EBITDA
$2.84M
Operating Cash Flow
$7.46M
Capital Expenditure
-$2.53M
Free Cash Flow
$4.93M
Cash & ST Invst.
$11.32M
Total Debt
$10.91M
Elite Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$31.59M
+119.9%
Gross Profit
$12.95M
+111.7%
Gross Margin
41.01%
N/A
Market Cap
$365.29M
N/A
Market Cap/Employee
$5.71M
N/A
Employees
64
N/A
Net Income
$18.59M
+270.7%
EBITDA
$9.52M
+194.4%
Quarterly Fundamentals
Total Cash
$21.09M
+154.4%
Total Debt
$7.21M
-35.5%
Accounts Receivable
$48.53M
+163.0%
Inventory
$25.10M
+24.5%
Long Term Debt
$6.10M
+0.7%
Short Term Debt
$1.12M
-78.2%
Return on Assets
34.34%
N/A
Return on Invested Capital
44.23%
N/A
Free Cash Flow
-$5.48M
-415.6%
Operating Cash Flow
-$5.28M
-396.2%